Coding and non-coding glucocerebrosidase variants have an impact on cognitive decline in Parkinson’s disease
Objective: To evaluate the impact of genetic variants in the Glucocerebrosidase gene (GBA) on cognitive impairment in a large cohort of Parkinson's disease (PD) patients…Impaired eye voice coordination in spinocerebellar degeneration while reading aloud
Objective: In order to elucidate the cause of the impaired reading performance. Background: Deficit in reading performance in patients with spinocerebellar degeneration (SCD) has been…Changes of brain structure and cognition in individuals with possible prodromal Parkinson’s disease
Objective: Investigating brain structure and cognition in healthy individuals with positive Parkinson's disease (PD) risk markers (hyposmia, increased hyperechogenic area of the substantia nigra). Background:…Neuropsychology and magnetic resonance correlation in Parkinson´s disease mild cognitive impairment: Case-control study
Objective: Evaluate the relationship between magnetic resonance (MRI) abnormalities and neuropsychological assessment in Parkinson s disease mild cognitive impairment (PD-MCI) and controls with mild cognitive…Reliability of verbal and written trail test for individuals with Parkinson’s disease: Is it a good cognitive test?
Objective: To verify if the verbal trail test can replace the written trail test, seeing that individuals with PD show considerable motor abnormalities that can…Visual hallucinations may serve as a possible predictor for Parkinson’s disease dementia
Objective: To observe whether visual hallucinations serve as a predictor of Parkinson's disease dementia. Background: Visual hallucinations (VH) is one of non-motor symptoms in Parkinson's…Mild cognitive impairment in Parkinson’s disease: Impact on caregiver outcomes
Objective: To utilise the newly established the International Parkinson and Movement Disorder Society (MDS) Task Force diagnostic criteria for Mild Cognitive Impairment (MCI) in Parkinson's…Cognition and amyloid biomarker status in non-demented patients with Parkinson’s disease patients (PD) with or without subjective cognitive decline (SCD)
Objective: To compare the cognitive and Amyloid-beta 1-42 profile of non-demented Parkinson's disease patients (PD) reporting subjective cognitive decline (SCD) with or without concerns regarding…Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
Objective: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). Background: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of neurogenic…A randomized clinical trial of atomoxetine treatment for mild cognitive impairment (MCI) in Parkinson’s disease (PD)
Objective: To evaluate (1) safety and tolerability of ATM and (2) effects of ATM on attention and executive functioning in PD- MCI after 10 weeks…
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 117
- Next Page »